Citigroup
MRTX

Citigroup’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Citigroup’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-61,961
Closed -$3.64M – 5947
2023
Q4 		$3.64M Sell
61,961
-95,693
-61% -$5.38M ﹤0.01% 1806
2023
Q3 		$6.87M Buy
157,654
+89,950
+133% +$3.21M 0.01% 1282
2023
Q2 		$2.45M Sell
67,704
-91,289
-57% -$3.76M ﹤0.01% 2019
2023
Q1 		$5.91M Buy
158,993
+36,279
+30% +$1.63M ﹤0.01% 1412
2022
Q4 		$5.56M Buy
122,714
+43,552
+55% +$2.82M ﹤0.01% 1421
2022
Q3 		$5.53M Sell
79,162
-3,331
-4% -$246K ﹤0.01% 1498
2022
Q2 		$5.54M Buy
82,493
+61,894
+300% +$3.94M ﹤0.01% 1481
2022
Q1 		$1.69M Sell
20,599
-14,251
-41% -$1.46M ﹤0.01% 2506
2021
Q4 		$5.11M Buy
34,850
+16,238
+87% +$2.52M ﹤0.01% 1812
2021
Q3 		$3.29M Sell
18,612
-15,899
-46% -$2.56M ﹤0.01% 2101
2021
Q2 		$5.58M Buy
34,511
+5,056
+17% +$812K ﹤0.01% 1812
2021
Q1 		$5.05M Sell
29,455
-40,395
-58% -$8M ﹤0.01% 1781
2020
Q4 		$15.3M Buy
69,850
+60,970
+687% +$13.2M 0.01% 1225
2020
Q3 		$1.47M Sell
8,880
-39,882
-82% -$5.46M ﹤0.01% 2936
2020
Q2 		$5.57M Buy
48,762
+13,217
+37% +$1.28M ﹤0.01% 1767
2020
Q1 		$2.73M Buy
35,545
+3,918
+12% +$351K ﹤0.01% 2189
2019
Q4 		$4.08M Sell
31,627
-14,110
-31% -$1.36M ﹤0.01% 2212
2019
Q3 		$3.56M Sell
45,737
-12,098
-21% -$1.14M ﹤0.01% 2252
2019
Q2 		$5.96M Buy
57,835
+49,508
+595% +$3.85M ﹤0.01% 1831
2019
Q1 		$609K Sell
8,327
-154,762
-95% -$10.5M ﹤0.01% 3969
2018
Q4 		$6.92M Buy
163,089
+103,125
+172% +$4.11M 0.01% 1555
2018
Q3 		$2.82M Buy
59,964
+35,333
+143% +$1.97M ﹤0.01% 2410
2018
Q2 		$1.21M Sell
24,631
-1,992
-7% -$75.2K ﹤0.01% 3150
2018
Q1 		$818K Sell
26,623
-14,901
-36% -$414K ﹤0.01% 3455
2017
Q4 		$758K Buy
+41,524
New +$644K ﹤0.01% 3633
2017
Q3 		– Sell
-1
Closed – – 7502
2017
Q2 		$0 Sell
1
-224
-100% -$858 ﹤0.01% 7526
2017
Q1 		$1K Buy
225
+25
+13% +$137 ﹤0.01% 7122
2016
Q4 		$1K Buy
200
+9
+5% +$49 ﹤0.01% 7142
2016
Q3 		$1K Sell
191
-400
-68% -$2.13K ﹤0.01% 7003
2016
Q2 		$3K Sell
591
-11,937
-95% -$190K ﹤0.01% 6887
2016
Q1 		$269K Buy
12,528
+7,288
+139% +$163K ﹤0.01% 4804
2015
Q4 		$166K Sell
5,240
-336,581
-98% -$11.9M ﹤0.01% 4916
2015
Q3 		$11.8M Buy
341,821
+339,406
+14,054% +$10.3M 0.01% 1024
2015
Q2 		$76K Buy
2,415
+1,945
+414% +$57.3K ﹤0.01% 5215
2015
Q1 		$13K Sell
470
-761
-62% -$17.9K ﹤0.01% 6348
2014
Q4 		$23K Buy
1,231
+981
+392% +$16.5K ﹤0.01% 6150
2014
Q3 		$4K Buy
250
+189
+310% +$3.53K ﹤0.01% 6672
2014
Q2 		$1K Buy
61
+32
+110% +$618 ﹤0.01% 6980
2014
Q1 		$1K Buy
+29
New +$603 ﹤0.01% 6903

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup's MRTX Position: Q1 2024 in Review

Citigroup sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 61,961 shares — an estimated $3.64M sold.

Citigroup first reported a position in MRTX in Q1 2014 and held it in 39 quarters. The position peaked at $15.3M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Citigroup reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citigroup sold 61,961 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.64M.
  • Citigroup first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2014 and held it in 39 quarters.
  • Citigroup's Mirati Therapeutics, Inc. Common Stock position peaked at $15.3M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.